عرض بسيط للتسجيلة

المؤلفAl-Ziftawi, Nour Hisham
المؤلفElazzazy, Shereen
المؤلفAlam, Mohammed Fasihul
المؤلفShafie, Asrul
المؤلفHamad, Anas
المؤلفBbujassoum, Salha
المؤلفMohamed Ibrahim, Mohamed Izham
تاريخ الإتاحة2024-03-13T13:38:03Z
تاريخ النشر2023
اسم المنشورFrontiers in Oncology
المصدرScopus
الرقم المعياري الدولي للكتاب2234943X
معرّف المصادر الموحدhttp://dx.doi.org/10.3389/fonc.2023.1203684
معرّف المصادر الموحدhttp://hdl.handle.net/10576/53045
الملخصIntroduction: Palbociclib and ribociclib are indicated in the first-line treatment of hormonal receptor-positive HER-2 negative (HR+/HER2- negative) advanced breast cancer. Although randomized-controlled trials (RCTs) proved their clinical efficacy, there are no observational studies yet to validate the clinical findings in the real-world. Therefore, this study aimed to evaluate and compare the clinical effectiveness and safety profiles of palbociclib and ribociclib in Qatar. Materials and methods: A retrospective observational study was conducted on HR+/HER-2-negative stage-IV breast cancer patients receiving palbociclib or ribociclib in the state of Qatar. Clinical data were collected from the National Center for Cancer Care and Research (NCCCR) in Qatar using Cerner. Primary outcomes were progression-free-survival (PFS) and overall-survival (OS) generated by Kaplan-Meier curves. Moreover, safety profiles of both two treatments were evaluated. Results: The data from 108 patients were included in the final analysis. There was no statistically significant difference in PFS between the palbociclib and ribociclib groups; PFS was 17.85 versus 13.55 months, respectively(p> 0.05). Similarly, there was no statistically significant difference in OS between the two medications, 29.82 versus 31.72 months, respectively(p>0.05). Adverse events were similar between the two groups. Neutropenia was the most common side effect in the study population accounting for 59.3% of the patients. Conclusions: Therefore, both treatments have similar efficacy and safety profiles. Further research on a larger-scale population and longer follow-up period is recommeneded.
راعي المشروعThe author(s) declare financial support was received for the research, authorship, and/or publication of this article. Hamad Medical Corporation.
اللغةen
الناشرFrontiers Media SA
الموضوعadvanced breast cancer (ABC)' CDK4/6 cell cycle inhibitors' cyclin-dependent-kinase 4/6 inhibitors' effectiveness & efficiency (E&E)' HR+/HER-2 negative
العنوانThe effectiveness and safety of palbociclib and ribociclib in stage IV HR+/HER-2 negative breast cancer: a nationwide real world comparative retrospective cohort study
النوعArticle
رقم المجلد13
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة